Peter Attia· MD
an apoe4 carrier who may have a second hit could be a genetic second that they they're inheriting another protein that increases the risk of of alzheimer's disease now their path toward disease is much more accelerated
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
an apoe4 carrier who may have a second hit could be a genetic second that they they're inheriting another protein that increases the risk of of alzheimer's disease now their path toward disease is much more accelerated
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.